Journal
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
Volume 30, Issue 1, Pages 52-56Publisher
WILEY-BLACKWELL
DOI: 10.1002/hup.2450
Keywords
bipolar disorder; bipolar depression; lithium; sTNFR1; sTNFR2
Funding
- CNPq
- Minas Gerais Research Foundation (Fapemig)
- Sao Paulo Research Foundation (Fapesp, Brazil) [2009/14891-9]
- NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002927] Funding Source: NIH RePORTER
Ask authors/readers for more resources
ObjectiveTNF system (TNF and its soluble receptors sTNFR1 and 2) has been investigated as a potential molecular target in bipolar disorder. The aim of the study was to compare plasma levels of these receptors in unmedicated bipolar depressed patients compared with healthy controls, and to evaluate the effects of a 6-week lithium treatment on sTNFR1 and sTNFR2 levels. MethodsThe study enrolled 29 patients with unmedicated bipolar disorder in a major depressive episode and 27 matched controls. Patients had blood collected at baseline and after 6weeks of lithium treatment. The concentration of sTNFRs was measured by ELISA. ResultssTNFR1 and sTNFR2 levels were significantly increased in bipolar depression in comparison with healthy subjects. Lithium treatment did not significantly change sTNFR1 and sTNFR2 levels from baseline to endpoint. There was no correlation between improvement in depressive symptoms and the change in sTNFR1 or sTNFR1 levels. ConclusionThese results reinforce the involvement of an activated immune response system in the pathophysiology of bipolar disorder, with no impact of lithium treatment on the related biomarkers. Copyright (c) 2014 John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available